Twice per Year HIV Antiretroviral

My take: Effective, safe, and twice-per-year dosing, though cost may be the limiting factor

Name: Lenacapavir

Class: Capsid Inhibitor (Antiretroviral Agent)

Method of Action: Lenacapavir inhibits the HIV-1 capsid protein, disrupting multiple stages of the viral lifecycle, including capsid-mediated nuclear import, viral genome integration, and capsid assembly. This unique mechanism makes it effective even against strains resistant to other classes of antiretroviral drugs.

Potential Market: Lenacapavir is primarily targeted for use in individuals with multidrug-resistant HIV-1 who have limited treatment options. It also has potential use in broader HIV treatment and prevention markets due to its infrequent dosing schedule.Competing Agents: Other antiretroviral classes including integrase strand transfer inhibitors (e.g., dolutegravir), protease inhibitors (e.g., darunavir), and reverse transcriptase inhibitors (e.g., tenofovir, efavirenz). However, no other currently approved agent shares lenacapavir’s specific capsid-targeting mechanism.

Cost to Consumer: Estimated annual cost is approximately $28,000 to $42,250 (U.S. price for Sunlenca), though actual costs vary depending on insurance and assistance programs.

Interesting Facts:

• Lenacapavir (brand name Sunlenca) is the first-in-class capsid inhibitor approved by the FDA in December 2022.

• It is administered as a subcutaneous injection every 6 months, making it the longest-acting HIV treatment currently approved.

• Its novel mechanism and infrequent dosing offer significant benefits for adherence, especially in populations with complex treatment histories.